日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

在富含高危疾病的初治慢性淋巴细胞白血病患者人群中开展的阿卡替尼、维奈克拉和奥妥珠单抗的II期研究

Davids, Matthew S; Ryan, Christine E; Lampson, Benjamin L; Ren, Yue; Tyekucheva, Svitlana; Fernandes, Stacey M; Crombie, Jennifer L; Kim, Austin I; Weinstock, Matthew; Montegaard, Josie; Walker, Heather A; Greenman, Claire; Patterson, Victoria; Jacobson, Caron A; LaCasce, Ann S; Armand, Philippe; Fisher, David C; Lo, Steve; Olszewski, Adam J; Arnason, Jon E; Ahn, Inhye E; Brown, Jennifer R

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

一项评估伊布替尼联合氟达拉滨、环磷酰胺和利妥昔单抗作为慢性淋巴细胞白血病一线治疗方案的II期研究的五年随访结果

Ahn, Inhye E; Brander, Danielle M; Ren, Yue; Zhou, Yinglu; Tyekucheva, Svitlana; Walker, Heather A; Black, Robert; Montegaard, Josie; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A; Armand, Philippe; Ng, Samuel Y; Crombie, Jennifer; Fisher, David C; LaCasce, Ann S; Arnason, Jon; Hochberg, Ephraim P; Takvorian, Ronald W; Abramson, Jeremy S; Brown, Jennifer R; Davids, Matthew S

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

维奈托克联合剂量调整的R-EPOCH方案治疗里氏综合征

Davids, Matthew S; Rogers, Kerry A; Tyekucheva, Svitlana; Wang, Zixu; Pazienza, Samantha; Renner, Sarah K; Montegaard, Josie; Ihuoma, Udochukwu; Lehmberg, Timothy Z; Parry, Erin M; Wu, Catherine J; Jacobson, Caron A; Fisher, David C; Thompson, Philip A; Brown, Jennifer R

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

一项针对年轻慢性淋巴细胞白血病患者的杜维利西布联合FCR方案(DFCR)一线治疗的1b/2期研究

Davids, Matthew S; Fisher, David C; Tyekucheva, Svitlana; McDonough, Mikaela; Hanna, John; Lee, Brandon; Francoeur, Karen; Montegaard, Josie; Odejide, Oreofe; Armand, Philippe; Arnason, Jon; Brown, Jennifer R